ANDA 208396, held by Apotex. Erlotinib Hydrochloride.
As of Nov 22, 2026, ANDA 208396 (Erlotinib Hydrochloride), held by Apotex, was first approved by FDA on Nov 5, 2019, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 5, 2019 | Original application | Approved | None posted |
| Erlotinib HydrochlorideEQ 25MG BASE · tablet;oral | Erlotinib Hydrochloride | Discontinued |
| Erlotinib HydrochlorideEQ 100MG BASE · tablet;oral | Erlotinib Hydrochloride | Discontinued |
| Erlotinib HydrochlorideEQ 150MG BASE · tablet;oral | Erlotinib Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters